Ipamorelin Research Hub · Evidence Overview

Ipamorelin research evidence: what has actually been studied?

A review of ipamorelin pharmacology, healthy-volunteer data, and a controlled postoperative study—without extending findings beyond the tested protocols.

JD BioWorks Research LibraryPublished: July 15, 2026Last reviewed: July 15, 2026Editorial review: JD BioWorks Research Library

Evidence at a glance

Human evidenceLimited but includes healthy-volunteer PK/PD work and a randomized phase 2 postoperative-ileus study.

Preclinical evidenceReceptor and animal studies examine ghrelin-receptor agonism, GH release, selectivity, and gastrointestinal motility.

Evidence gapThe controlled postoperative trial did not show a statistically significant difference on its key efficacy endpoint. Long-term evidence is limited.

ScopeEvidence from intravenous clinical protocols does not establish effects for other formulations, routes, or combinations.

Interpretation note: Findings must stay tied to the exact molecule, formulation, model, population, and endpoint studied. A biological signal is not, by itself, proof of safety or effectiveness.

Overview

Ipamorelin is a synthetic peptide studied as a growth-hormone secretagogue and ghrelin-receptor agonist. Research questions include pharmacokinetics, concentration–effect relationships, endocrine response, receptor selectivity, and gastrointestinal motility. Its combination with a GHRH analogue is a distinct research system; evidence for either component alone does not prove a combined effect.

Research background

Early human work used short intravenous infusions in healthy male volunteers to model exposure and GH response. Later, a multicenter randomized phase 2 study evaluated intravenous ipamorelin after bowel resection. The trial provides a useful example of why mechanistic plausibility and early pharmacology do not guarantee success on a clinical endpoint.

Findings by research area

Research area	What has been reported	What it does not establish
Healthy volunteers	Dose-escalation infusions produced data for PK/PD modeling and GH response.	Long-term safety or clinical benefit.
Postoperative trial	A randomized double-blind study enrolled 117 patients after bowel resection.	Efficacy: the primary endpoint difference was not statistically significant.
Combination research	Ipamorelin is sometimes studied or supplied with GHRH analogues.	That single-agent data predict the combined system.

Human evidence

Human data

A 1999 dose-escalation study used five infusion rates, with eight healthy male subjects at each level, to model ipamorelin pharmacokinetics and GH response. In the later postoperative-ileus trial, 117 patients were enrolled and 114 entered the modified intention-to-treat analysis. Median time to a tolerated standardized meal was numerically shorter with ipamorelin, but the difference was not statistically significant; secondary efficacy analyses also did not show significant differences.

Preclinical evidence

Animal data

Animal and isolated-tissue studies have examined GH release and gastrointestinal motility. Species differences in ghrelin-receptor pharmacology, endocrine feedback, and postoperative physiology limit direct translation.

Laboratory evidence

In-vitro and analytical context

Receptor assays help characterize agonism and selectivity. They do not reproduce pulsatile endocrine regulation or provide in-vivo exposure and safety data.

Research limitations

Human studies are limited in number and scope.
The main controlled efficacy trial did not meet its key endpoint.
Short infusions do not establish long-term outcomes.
Combination products require separate characterization and cannot inherit conclusions from each ingredient.

Future research

Future work would require exact test-article characterization, reproducible PK/PD, prospectively defined endpoints, adequate power, and transparent reporting of both positive and negative results.

Primary references

Article record

Research question: What does the published evidence on Ipamorelin show across human, animal, and laboratory research?
Evidence cutoff: July 15, 2026
Article status: Published educational research summary; not independently peer reviewed
Author: JD BioWorks Research Library
Editorial review: JD BioWorks Research Library
Planned review cycle: At least annually, or sooner if material evidence or regulatory information changes

This article summarizes published research for educational and laboratory-information purposes. It is not medical advice, does not provide instructions for personal use, and does not establish that any material is safe or effective for human or veterinary use.

CONTINUE YOUR REVIEW

Next steps for qualified researchers

Use the public documentation resources below, then continue to Research Product Access when you are ready to review the gated catalog.

Search Certificates of Analysis Match available analytical records to the named product, quantity, and lot. Explore Research Guides Review HPLC, LC-MS, purity, identity, storage, and traceability guidance. Get Research Product Access Complete the Research Use Acknowledgment to create an account and receive automatic product access.

For qualified laboratory, analytical, educational, or institutional research only. Not for human or veterinary use.